CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

• Phase: Phase 2

Details

• Lead Sponsor: RSPR Pharma AB

Criteria

Inclusion Criteria:

• Documented diagnosis of dystrophinopathy

Exclusion Criteria:

• Severe functional impairment